The Bayer biotech company has experienced a thriving growth period, charting an estimated 40% rebound after several years of losses. The company's stock value went through a slump after being ordered to pay more than $2 billion over the Roundup case, contributing to a drop to a 20-year low in the stock's value in line with the 2025 earnings fall forecast. However, Bayer's shares have started to gain traction thanks to a positive growth forecast starting in FY26, despite the Q4 loss and cautious FY25 outlook.
Pharmaceutical strength is one of the main drivers of this surge, contributing to Q1 results beating estimates despite some losses incurred by the Crop Science Unit. This upward trend has led to Goldman Sachs upgrading Bayer's stock rating from 'Hold' to 'Buy'. Despite some turbulence caused by ongoing US lawsuits and subsequent cash raising plans, which temporarily saw a 10% plunge in the shares, share performance is still outperforming other companies in the medical sector this year after the announcement of successful results in several fields, including the treatment for AMD and DMO.
BAYER Stocks News Analytics from Fri, 16 Aug 2024 07:00:00 GMT to Fri, 27 Jun 2025 08:21:12 GMT - Rating 6 - Innovation 4 - Information 7 - Rumor -3